Evaluation of the transparency committeeCISMeF resources Type

https://www.has-sante.fr/jcms/p_3605179/fr/tagrisso-osimertinib-cancer-du-poumon
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
osimertinib
antineoplastic agents
Tyrosine Kinase Inhibitors
adult
EGFR Exon 19 Deletion Mutation
EGFR NP_005219.2:p.L858R
Locally Advanced Unresectable Lung Non-Small Cell Carcinoma
lung neoplasms
Non-small cell lung cancer with mutation in epidermal growth factor receptor (disorder)
evaluation of the transparency committee
lung neoplasms
osimertinib

---
https://www.has-sante.fr/jcms/p_3605173/fr/zutectra-immunoglobuline-humaine-de-l-hepatite-b-prevention-de-la-reactivation-de-l-hepatite-b
2025
false
false
false
France
BT088 immunoglobulin, human
Reactivation of hepatitis B viral hepatitis (disorder)
hepatitis b immunoglobulin
injections, subcutaneous
treatment outcome
insurance, health, reimbursement
adult
liver transplantation
Entire transplanted liver (body structure)
Hepatitis B Virus Surface Antigen Negative
Hepatitis B DNA assay negative
hepatitis B
evaluation of the transparency committee
hepatitis B
immunoglobulins
hepatitis B hyperimmune globulin

---
https://www.has-sante.fr/jcms/p_3606853/fr/efluelda-vaccin-antigrippal-trivalent-inactive-a-virion-fragmente-60-g-ha/souche-vaccin-antigrippal
2025
France
evaluation of the transparency committee
Trivalent Influenza Vaccine
vaccines, inactivated
preventive immunization/medication
influenza vaccines
virion
influenza virus vaccine
fragmentation, nos
vaccination

---
https://www.has-sante.fr/jcms/p_3606850/fr/synjardy-empagliflozine/metformine-diabete-de-type-2-chez-les-enfants-ages-de-10-ans-et-plus
2025
France
evaluation of the transparency committee
child
diabetes mellitus, type 2
diabetes non-insulin dependent
child, nos

---
https://www.has-sante.fr/jcms/p_3575020/fr/tecartus-brexucabtagene-autoleucel-lymphome-a-cellules-du-manteau-lcm
2025
false
false
false
France
evaluation of the transparency committee
antigens, CD19
"u" lymphocyte
brexucabtagene autoleucel
brexucabtagene autoleucel
cells

---
https://www.has-sante.fr/jcms/p_3576429/fr/trumenba-vaccin-meningococcique-groupe-b-recombinant-adsorbe-vaccin-anti-meningococcique-serogroupe-b
2025
false
false
false
France
Meningococcal group B vaccine (product)
evaluation of the transparency committee
vaccines, recombinant
vaccination
Serogroup
preventive immunization/medication
neisseria meningitidis
meningococcal vaccines
vaccines, synthetic
vaccine, nos
population groups

---
https://www.has-sante.fr/jcms/p_3577039/fr/primaquine-sanofi-primaquine-phosphate-paludisme
2025
false
false
false
France
Product containing precisely primaquine (as primaquine phosphate) 15 milligram/1 each conventional release oral tablet (clinical drug)
insurance, health, reimbursement
treatment outcome
adult
adolescent
child
recurrence
antimalarials
Vivax Malaria
Ovale malaria (disorder)
primaquine
evaluation of the transparency committee
malaria
primaquine phosphate
primaquine

---
https://www.has-sante.fr/jcms/p_3576072/fr/padcev-enfortumab-vedotin-carcinome-urothelial
2025
false
false
false
France
Urothelial Carcinoma
evaluation of the transparency committee
enfortumab vedotin
carcinoma
enfortumab vedotin

---
https://www.has-sante.fr/jcms/p_3577021/fr/vabysmo-faricimab-oedeme-maculaire-secondaire-a-une-occlusion-de-branche-veineuse-retinienne-obvr-ou-de-la-veine-centrale-de-la-retine-ovcr
2025
false
false
false
France
faricimab
vision disorders
Central Retinal Vein Occlusion
intravitreal injections
adult
evaluation of the transparency committee
macular edema
faricimab
retinal vein occlusion
Branch Vein Occlusion

---
https://www.has-sante.fr/jcms/p_3576495/fr/spevigo-spesolimab-psoriasis-pustuleux-generalise-ppg
2025
false
false
false
France
insurance, health, reimbursement
treatment outcome
Generalized pustular psoriasis
Generalized pustular psoriasis flare
spesolimab
adult
adolescent
evaluation of the transparency committee
psoriasis
spesolimab

---
https://www.has-sante.fr/jcms/p_3574834/fr/tibsovo-ivosidenib-cancer-voies-biliaires
2025
false
false
false
France
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
evaluation of the transparency committee
ivosidenib
ivosidenib
biliary tract, nos
neoplasm, malignant
Tibsovo
biliary tract neoplasms
biliary tract cancer

---
https://www.has-sante.fr/jcms/p_3576108/fr/adzynma-apadamtase-alfa-purpura-thrombotique-thrombocytopenique-congenital-pttc-pediatrie
2025
false
false
false
France
child
treatment outcome
insurance, health, reimbursement
Apadamtase Alfa
guidelines for drug use
apadamtase alfa and cinaxadamtase alfa
Cinaxadamtase Alfa
enzyme replacement therapy
ADAMTS13 protein, human
injections, intravenous
evaluation of the transparency committee
purpura, thrombotic thrombocytopenic
congenital thrombotic thrombocytopenic purpura

---
https://www.has-sante.fr/jcms/p_3508311/fr/winrevair-sotatercept-hypertension-arterielle-pulmonaire
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug therapy, combination
sotatercept
evaluation of the transparency committee
Pulmonary Arterial Hypertension
sotatercept

---
https://www.has-sante.fr/jcms/p_3576306/fr/imfinzi-durvalumab-et-lynparza-olaparib-en-association-cancer-de-l-endometre
2025
false
false
false
France
evaluation of the transparency committee
olaparib
cancer
Imfinzi
endometrial neoplasms
durvalumab
Lynparza
endometrium
neoplasm, malignant
olaparib
association
olaparib
durvalumab
Endomet

---
https://www.has-sante.fr/jcms/p_3576102/fr/sam-de-l-ansm-sur-le-valproate-modification-des-conditions-de-prescription-et-de-delivrance-cpd-pour-les-patients-adolescents-et-hommes-afin-de-limiter-les-risques-potentiels-de-troubles-neurodeveloppementaux-pour-les-enfants-a-naitre-lies-a-l-exposition-paternelle-dans-les-trois-mois-precedant-la-conception
2025
France
evaluation of the transparency committee
indexing
medical futility
child
conception
meconium aspiration syndrome
adolescence
patients
macrophage activation syndrome
risk
paternal exposure
prescription, nos
men
adolescent
Neurodevelopmental Disorders
decision support techniques
father, nos
drug design
operations research
drug, nos
valproic acid
valproate
has patient
delivery, obstetric
effects of exposure to external cause, nos
mosaic variegated aneuploidy syndrome
Abstracting and Indexing
child, nos
valproate

---
https://www.has-sante.fr/jcms/p_3576148/fr/sam-de-l-ansm-sur-la-carbamazepine-modification-des-conditions-de-prescription-et-de-delivrance-cpd-pour-les-patientes-afin-de-reduire-les-risques-malformatifs-lies-a-l-exposition-in-utero
2025
France
evaluation of the transparency committee
professional practice
congenital abnormalities
prescription, nos
pharmaceutical preparations
operations research
indexing
macrophage activation syndrome
carbamazepine
risk
tool, nos
Exhibition
decision support techniques
meconium aspiration syndrome
patients
uterus, nos
carbamazepine
has patient
mosaic variegated aneuploidy syndrome
delivery, obstetric
developmental anomaly, nos
drug, nos
effects of exposure to external cause, nos
Abstracting and Indexing

---
https://www.has-sante.fr/jcms/p_3576200/fr/iqirvo-elafibranor-cholangite-biliaire-primitive-cbp
2025
false
false
false
France
drug therapy, combination
evaluation of the transparency committee
cholangitis
elafibranor
Primary Biliary Cholangitis

---
https://www.has-sante.fr/jcms/p_3576525/fr/ogsiveo-nirogacestat-tumeurs-desmoides
2025
false
false
false
France
nirogacestat
treatment outcome
insurance, health, reimbursement
Tumor Progression
Refractory Desmoid Fibromatosis
adult
administration, oral
Gamma Secretase Inhibitors
nirogacestat
evaluation of the transparency committee
ogsiveo
Desmoid Tumors

---
https://www.has-sante.fr/jcms/p_3576557/fr/vyloy-zolbetuximab-adenocarcinome-gastrique-et-de-la-jonction-oesogastrique
2025
false
false
false
France
antineoplastic combined chemotherapy protocols
treatment outcome
insurance, health, reimbursement
adult
Fluoropyrimidine
platinum salt, nos
Gastric Adenocarcinoma
stomach neoplasms
Gastroesophageal Junction Adenocarcinoma
esophageal neoplasms
HER2/Neu Negative
CLDN18.2 Positive
infusions, intravenous
zolbetuximab
evaluation of the transparency committee
zolbetuximab
adenocarcinoma

---
https://www.has-sante.fr/jcms/p_3574250/fr/eladynos-abaloparatide-osteoporose
2025
false
false
false
France
abaloparatide
Product containing only abaloparatide in parenteral dose form (medicinal product form)
treatment outcome
insurance, health, reimbursement
osteoporotic fractures
History of vertebral fracture (situation)
History of osteoporotic fracture (situation)
injections, subcutaneous
bone density conservation agents
evaluation of the transparency committee
osteoporosis, postmenopausal
abaloparatide

---
https://www.has-sante.fr/jcms/p_3576426/fr/viperfav-fragment-f-ab-2-d-immunoglobulines-equines-antivenimeuses-de-viperes-europeennes-vipera-aspis-vipera-berus-vipera-ammodytes-immunoglobulines
2025
false
false
false
France
immunoglobulin fab fragments
treatment outcome
insurance, health, reimbursement
snake venom antiserum
snake bites
Snakebite envenomation
infusions, intravenous
evaluation of the transparency committee
european viper

---
https://www.has-sante.fr/jcms/p_3577033/fr/glycerophosphate-de-sodium-kabi-glycerophosphate-de-sodium-anhydre-solution-d-electrolytes
2025
false
false
false
France
Sodium Glycerophosphate Anhydrous
treatment outcome
insurance, health, reimbursement
adult
infant, newborn
infant
child
adolescent
hypophosphatemia
Phosphorus supplement therapy (regime/therapy)
parenteral nutrition
infusions, intravenous
sodium glycerophosphate
evaluation of the transparency committee
sodium glycerophosphate
electrolytes
alpha-glycerophosphoric acid
glycerophosphates

---
https://www.has-sante.fr/jcms/p_3577027/fr/nomanesit-sumatriptan/naproxene-migraine
2025
false
false
false
France
sumatriptan-naproxen
sumatriptan succinate
naproxen sodium
administration, oral
insurance, health, reimbursement
treatment outcome
migraine without aura
sumatriptan and naproxen
adult
drug combinations
evaluation of the transparency committee
migraine with aura

---
https://www.has-sante.fr/jcms/p_3577030/fr/benlysta-belimumab-lupus-systemique-actif
2025
false
false
false
France
belimumab
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
belimumab

---
https://www.has-sante.fr/jcms/p_3574253/fr/ventoline-salbutamol-asthme
2025
false
false
false
France
injections, subcutaneous
acute disease
evaluation of the transparency committee
albuterol
asthma

---
https://www.has-sante.fr/jcms/p_3576262/fr/jakavi-ruxolitinib-maladie-du-greffon-pediatrie
2025
false
false
false
France
administration, oral
pharmaceutical solutions
graft vs host disease
child
ruxolitinib
Janus Kinase Inhibitors
evaluation of the transparency committee
ruxolitinib

---
https://www.has-sante.fr/jcms/p_3577036/fr/kalydeco-ivacaftor-mucoviscidose
2025
false
false
false
France
infant
treatment outcome
insurance, health, reimbursement
administration, oral
ivacaftor
evaluation of the transparency committee
cystic fibrosis
ivacaftor

---
https://www.has-sante.fr/jcms/p_3576423/fr/pheburane-phenylbutyrate-de-sodium-desordres-du-cycle-de-l-uree
2025
false
false
false
France
pharmaceutical solutions
administration, oral
treatment outcome
insurance, health, reimbursement
sodium phenylbutyrate
4-phenylbutyric acid
carbamoyl-phosphate synthase i deficiency disease
citrullinemia
ornithine carbamoyltransferase deficiency disease
evaluation of the transparency committee
phenylbutyrates
4-phenylbutyric acid, sodium salt

---
https://www.has-sante.fr/jcms/p_3578491/fr/jemperli-dostarlimab-cancer-de-l-endometre
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
dostarlimab
antineoplastic combined chemotherapy protocols
Carboplatin/Dostarlimab/Paclitaxel Regimen
carboplatin
paclitaxel
Mismatch Repair Deficiency
High-Frequency Microsatellite Instability
adult
infusions, intravenous
antineoplastic agents
evaluation of the transparency committee
dostarlimab
endometrial neoplasms

---
https://www.has-sante.fr/jcms/p_3578966/fr/briumvi-ublituximab-sclerose-en-plaques
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
ublituximab
adult
infusions, intravenous
evaluation of the transparency committee
multiple sclerosis, relapsing-remitting
ublituximab

---
https://www.has-sante.fr/jcms/p_3578470/fr/amikacine-panpharma-amikacine-antibacterien-aminoside
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
amikacin
Product containing precisely amikacin (as amikacin sulfate) 250 milligram/1 milliliter conventional release solution for injection (clinical drug)
infusions, intravenous
injections, intramuscular
evaluation of the transparency committee
anti-bacterial agents
amikacin

---
https://www.inserm.fr/actualite/maladie-dalzheimer-un-nouvel-algorithme-pour-aider-a-depister-les-personnes-a-risque/
2025
France
evaluation of the transparency committee
persons
alzheimer disease
risk
alzheimer's disease, nos
homemaker services
algorithms
caregivers

---
https://www.inserm.fr/actualite/plaquettes-sanguines-une-production-sous-pression/
2025
France
evaluation of the transparency committee
economics
pressure, nos
platelet
production
blood platelets
blood pressure

---
https://www.has-sante.fr/jcms/p_3585759/fr/balversa-erdafitinib-carcinome-urothelial
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
erdafitinib
Product containing only erdafitinib in oral dose form (medicinal product form)
administration, oral
FGFR Inhibitor
receptors, fibroblast growth factor
adult
Unresectable Urothelial Carcinoma
Metastatic Urothelial Carcinoma
FGFR3 Gene Alteration Positive
receptor, fibroblast growth factor, type 3
Alteration of genetic material (finding)
evaluation of the transparency committee
Balversa
erdafitinib

---
https://www.has-sante.fr/jcms/p_3585496/fr/cosidime-dorzolamide-/-timolol
2025
false
false
false
France
dorzolamide hydrochloride-timolol maleate combination
timolol maleate
drug combinations
treatment outcome
insurance, health, reimbursement
glaucoma, open-angle
timolol, combinations
administration, ophthalmic
dorzolamide
evaluation of the transparency committee
dorzolamide hydrochloride
timolol
dorzolamide-timolol combination

---
https://www.has-sante.fr/jcms/p_3585762/fr/perprup-povidone-iodee-/-alcool-isopropylique-antiseptique
2025
false
false
false
France
administration, cutaneous
drug combinations
treatment outcome
insurance, health, reimbursement
antisepsis
adult
adolescent
child
antiseptics and disinfectants
evaluation of the transparency committee
anti-infective agents, local
2-Propanol
povidone-iodine

---
https://www.has-sante.fr/jcms/p_3586458/fr/kayfanda-odevixibat-traitement-du-prurit-cholestatique-associe-au-syndrome-d-alagille
2025
false
false
false
France
Odevixibat sesquihydrate (substance)
cholestatic pruritus in Alagille syndrome
Cholestatic pruritus (disorder)
infant
child
adult
administration, oral
treatment outcome
insurance, health, reimbursement
odevixibat
evaluation of the transparency committee
pruritus
odevixibat
alagille syndrome

---
https://www.has-sante.fr/jcms/p_3586231/fr/adzynma-adamts13r-purpura-thrombotique-thrombocytopenique-congenital-pttc
2025
false
false
false
France
ADAMTS13 Protein
Apadamtase Alfa
enzyme replacement therapy
congenital thrombotic thrombocytopenic purpura
adult
child
treatment outcome
insurance, health, reimbursement
orphan drug production
injections, intravenous
Congenital thrombotic thrombocytopenic purpura
evaluation of the transparency committee
purpura, thrombotic thrombocytopenic

---
https://www.has-sante.fr/jcms/p_3586461/fr/bifonazole-substipharm-bifonazole-antifongique-topique
2025
false
false
false
France
administration, cutaneous
insurance, health, reimbursement
treatment outcome
bifonazole
adult
adolescent
child
infant
dermatomycoses
tinea
tinea versicolor
candidiasis, cutaneous
candidiasis, chronic mucocutaneous
Mucocutaneous Candidiasis
evaluation of the transparency committee
bifonazole
antifungal agents

---
https://www.has-sante.fr/jcms/p_3587072/fr/krazati-adagrasib-cancer-bronchique-non-a-petites-cellules
2025
false
false
false
France
adagrasib
KRAS NP_004976.2:p.G12C
KRAS Gene Mutation
evaluation of the transparency committee
adagrasib
carcinoma, non-small-cell lung

---
https://www.has-sante.fr/jcms/p_3587094/fr/tibsovo-ivosidenib-cancer-voies-biliaires
2025
false
false
false
France
Locally Advanced Cholangiocarcinoma
treatment outcome
insurance, health, reimbursement
cholangiocarcinoma
ivosidenib
adult
Metastatic Cholangiocarcinoma
IDH1 NP_005887.2:p.R132X
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
administration, oral
antineoplastic agents
evaluation of the transparency committee
ivosidenib

---
https://www.has-sante.fr/jcms/p_3588262/fr/colprone-medrogestone-gynecologie
2025
false
false
false
France
evaluation of the transparency committee
medrogestone
gynecology
colprone

---
https://www.has-sante.fr/jcms/p_3589090/fr/tiotropium-eg-vertical-haler-tiotropium-bronchopneumopathie-chronique-obstructive-bpco
2025
false
false
false
France
powders
treatment outcome
insurance, health, reimbursement
administration, inhalation
tiotropium bromide
evaluation of the transparency committee
pulmonary disease, chronic obstructive
Tiotropium Bromide

---
https://www.has-sante.fr/jcms/p_3527462/fr/retsevmo-selpercatinib-cancer-de-la-thyroide
2025
false
false
false
France
adult
adolescent
treatment outcome
insurance, health, reimbursement
administration, oral
selpercatinib
advanced RET fusion-positive thyroid cancer
RET Fusion Positive
thyroid cancer, medullary
carcinoma, neuroendocrine
Advanced Thyroid Gland Medullary Carcinoma
RET Inhibitor
antineoplastic agents
evaluation of the transparency committee
selpercatinib
thyroid neoplasms

---
https://www.has-sante.fr/jcms/p_3589534/fr/skyclarys-omaveloxolone-traitement-de-l-ataxie-de-friedreich-af
2025
false
false
false
France
omaveloxolone
evaluation of the transparency committee
friedreich's ataxia
Omaveloxolone
Omaveloxolone
friedreich ataxia

---
https://www.has-sante.fr/jcms/p_3588817/fr/iqirvo-elafibranor-cholangite-biliaire-primitive
2025
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
Primary Biliary Cholangitis
drug therapy, combination
ursodeoxycholic acid
adult
elafibranor
evaluation of the transparency committee
elafibranor

---
https://www.has-sante.fr/jcms/p_3589751/fr/agilus-dantrolene-sodique-hemiheptahydrate-anesthesie
2025
false
false
false
France
Dantrolene sodium, hemiheptahydrate
insurance, health, reimbursement
treatment outcome
adult
child
adolescent
Malignant hyperpyrexia caused by anesthetic (disorder)
anesthetics
malignant hyperthermia
infant
dantrolene
Product containing only dantrolene in parenteral dose form (medicinal product form)
evaluation of the transparency committee
Dantrolene Sodium
dantrolene

---
https://www.has-sante.fr/jcms/p_3589935/fr/kinox-monoxyde-d-azote-vasodilatateur-inhale
2025
false
false
false
France
adult
infant, newborn
adolescent
child
infant
nitric oxide
perioperative pulmonary hypertension
postoperative pulmonary hypertension
cardiac surgical procedures
evaluation of the transparency committee
nitric oxide
administration, inhalation
hypertension, pulmonary
respiratory distress syndrome, newborn

---
https://www.has-sante.fr/jcms/p_3590642/fr/pepaxti-melphalan-flufenamide-myelome-multiple
2025
false
false
false
France
insurance, health, reimbursement
treatment outcome
phenylalanine
antineoplastic agents
melphalan flufenamide
antineoplastic combined chemotherapy protocols
Dexamethasone/Melphalan Flufenamide Regimen
Triple-Class Refractory Multiple Myeloma
evaluation of the transparency committee
melflufen
multiple myeloma
melphalan

---
https://www.has-sante.fr/jcms/p_3591339/fr/ofriri-dorzolamide-hypertonie-oculaire-glaucome-a-angle-ouvert-glaucome-pseudo-exfoliatif
2025
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, ophthalmic
ocular hypertension
exfoliation syndrome
dorzolamide
evaluation of the transparency committee
glaucoma, open-angle
dorzolamide

---
https://www.has-sante.fr/jcms/p_3542801/fr/blincyto-blinatumomab-leucemie-aigue-lymphoblastique
2025
false
false
false
France
blinatumomab
antineoplastic agents
adult
treatment outcome
insurance, health, reimbursement
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Measurable Residual Disease Negativity
consolidation chemotherapy
evaluation of the transparency committee
precursor cell lymphoblastic Leukemia-Lymphoma
blinatumomab

---
https://www.has-sante.fr/jcms/p_3556159/fr/dupixent-dupilumab-bronchopneumopathie-chronique-obstructive-bpco
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
injections, subcutaneous
evaluation of the transparency committee
dupilumab
pulmonary disease, chronic obstructive

---
https://www.has-sante.fr/jcms/p_3431851/fr/xenpozyme-olipudase-alfa-deficit-en-sphingomyelinase-acide
2025
false
false
false
France
evaluation of the transparency committee
sphingomyelin/cholesterol lipidosis, nos
xenpozyme
acid, nos
olipudase alfa
niemann-pick diseases
olipudase alfa

---
https://www.has-sante.fr/jcms/p_3417653/fr/livtencity-maribavir-infection-a-cmv
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
maribavir
cytomegalovirus infections
antiviral agents
Product containing only maribavir (medicinal product)
adult
organ transplantation
hematopoietic stem cell transplantation
Refractory Cytomegalovirus Infection
administration, oral
evaluation of the transparency committee
maribavir

---
https://www.has-sante.fr/jcms/p_3606847/fr/evrysdi-risdiplam-amyotrophie-spinale-sma
2025
France
evaluation of the transparency committee
Risdiplam
Risdiplam
spinal muscular atrophy, nos
muscular atrophy, spinal

---
https://www.has-sante.fr/jcms/p_3606289/fr/winrevair-sotatercept-hypertension-arterielle-pulmonaire-htap
2025
France
evaluation of the transparency committee
pulmonary hypertension, nos
sotatercept
Pulmonary Arterial Hypertension
hypertensive disease, nos

---
https://www.has-sante.fr/jcms/p_3607243/fr/sivextro-phosphate-de-tedizolid-antibiotiques
2025
France
evaluation of the transparency committee
tedizolid phosphate
antibiotic, nos
anti-bacterial agents
Sivextro
phosphates
Phosphate
tedizolid phosphate
antibiotics

---
https://www.has-sante.fr/jcms/p_3606155/fr/tixtar-rifaximine-encephalopathie-hepatique
2025
France
evaluation of the transparency committee
Rifaximin
hepatic encephalopathy
hepatic encephalopathy

---
https://www.has-sante.fr/jcms/p_3606844/fr/fluad-vaccin-trivalent-antigrippal-antigenes-de-surface-inactive-avec-adjuvant-vaccin-antigrippal
2025
France
evaluation of the transparency committee
influenza vaccines
adjuvant, nos
preventive immunization/medication
vaccination
hepatitis surface antigen
Trivalent Influenza Vaccine
antigens, surface
influenza virus vaccine

---
https://www.has-sante.fr/jcms/p_3591600/fr/olatalin-dorzolamide/timolol-glaucome-a-angle-ouvert-glaucome-pseudo-exfoliatif
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
dorzolamide-timolol combination
dorzolamide
timolol
drug combinations
administration, ophthalmic
timolol, combinations
evaluation of the transparency committee
exfoliation syndrome
glaucoma, open-angle

---
https://www.has-sante.fr/jcms/p_3590911/fr/glucose-aguettant-glucose-solute
2025
false
false
false
France
infusions, intravenous
insurance, health, reimbursement
treatment outcome
carbohydrates
evaluation of the transparency committee
glucose

---
https://www.has-sante.fr/jcms/p_3590636/fr/imfinzi-durvalumab-cancer-de-l-endometre
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
durvalumab
antineoplastic combined chemotherapy protocols
Mismatch Repair Deficiency
adult
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
neoplasm recurrence, local
infusions, intravenous
evaluation of the transparency committee
durvalumab
endometrial neoplasms

---
https://www.has-sante.fr/jcms/p_3591345/fr/relistor-bromure-de-methylnaltrexone-constipation-liee-aux-opioides
2025
false
false
false
France
insurance, health, reimbursement
treatment outcome
methylnaltrexone bromide
injections, subcutaneous
adult
evaluation of the transparency committee
Opioid-Induced Constipation
methylnaltrexone
naltrexone methylbromide

---
https://www.has-sante.fr/jcms/p_3590639/fr/imfinzi-lynparza-durvalumab/olaparib-cancer-de-l-endometre
2025
false
false
false
France
antineoplastic combined chemotherapy protocols
insurance, health, reimbursement
treatment outcome
Antineoplastic Agents, Immunological
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
Mismatch Repair Proficient
Mismatch Repair Deficiency
durvalumab
durvalumab
olaparib
olaparib
evaluation of the transparency committee
endometrial neoplasms

---
https://www.has-sante.fr/jcms/p_3590908/fr/chlorure-de-sodium-aguettant-chlorure-de-sodium-solute
2025
false
false
false
France
evaluation of the transparency committee
solutions
urine chloride
sodium chloride
sodium chloride
solution, nos

---
https://www.has-sante.fr/jcms/p_3592928/fr/amvuttra-vutrisiran-amylose-hereditaire-a-transthyretine-avec-cardiomyopathie
2025
false
false
false
France
amyloid neuropathies, familial
evaluation of the transparency committee
amylose
amyloidosis, hereditary, Transthyretin-Related
cardiomyopathies

---
https://www.has-sante.fr/jcms/p_3592956/fr/tepezza-teprotumumab-ophtalmopathie-basedowienne
2025
false
false
false
France
evaluation of the transparency committee
graves ophthalmopathy
tepezza
teprotumumab

---
https://www.has-sante.fr/jcms/p_3592985/fr/elahere-mirvetuximab-soravtansine-cancer-de-l-ovaire
2025
false
false
false
France
insurance, health, reimbursement
mirvetuximab soravtansine
infusions, intravenous
adult
fallopian tube neoplasms
peritoneal neoplasms
Folate Receptor Alpha Positive
evaluation of the transparency committee
ovarian neoplasms
mirvetuximab soravtansine

---
https://www.has-sante.fr/jcms/p_3594390/fr/vitrakvi-larotrectinib-sarcome-des-tissus-mous-cancer-des-glandes-salivaires-cancer-de-la-thyroide-non-medullaire
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
Tyrosine Kinase Inhibitors
larotrectinib
TRK Inhibitor
nonmedullary thyroid carcinoma
adult
NTRK Fusion Gene Positive
Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion (disorder)
evaluation of the transparency committee
salivary gland neoplasms
larotrectinib
sarcoma
thyroid neoplasms

---
https://www.has-sante.fr/jcms/p_3594381/fr/rystiggo-rozanolixizumab-myasthenie
2025
false
false
false
France
drug therapy, combination
adult
treatment outcome
insurance, health, reimbursement
immunosuppressive agents
rozanolixizumab
generalised myasthenia gravis with anti-acetylcholine receptor antibody
Adult-onset myasthenia gravis
infusions, subcutaneous
evaluation of the transparency committee
myasthenia gravis
rozanolixizumab

---
https://www.has-sante.fr/jcms/p_3594155/fr/vyloy-zolbetuximab-adenocarcinome-gastrique-et-de-la-jonction-oesogastrique
2025
false
false
false
France
stomach neoplasms
esophageal neoplasms
treatment outcome
insurance, health, reimbursement
zolbetuximab
infusions, intravenous
Antineoplastic Agents, Immunological
antineoplastic combined chemotherapy protocols
adult
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
CLDN18.2 Positive
HER2/Neu Negative
evaluation of the transparency committee
adenocarcinoma
zolbetuximab
esophagogastric junction

---
https://www.has-sante.fr/jcms/p_3594378/fr/nilemdo-acide-bempedoique-dyslipidemie
2025
false
false
false
France
adult
risk
treatment outcome
insurance, health, reimbursement
bempedoic acid
nilemdo
Heart Disease Risk Factors
primary prevention
secondary prevention
cardiovascular diseases
Atherosclerotic Cardiovascular Disease
administration, oral
Product containing precisely bempedoic acid 180 milligram/1 each conventional release oral tablet (clinical drug)
evaluation of the transparency committee
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
hypercholesterolemia

---
https://www.has-sante.fr/jcms/p_3594714/fr/flucelvax-tiv-vaccin-grippal-inactive-antigene-de-surface-prepare-sur-cultures-cellulaires-vaccin-antigrippal
2025
false
false
false
France
Trivalent Influenza Vaccine
Antigen of Influenza virus surface protein (substance)
insurance, health, reimbursement
vaccine potency
influenza, human
vaccination
INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B
INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2)
INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1)
adult
child
evaluation of the transparency committee
antigens, surface
influenza vaccines
vaccination
vaccines, inactivated

---
https://www.has-sante.fr/jcms/p_3594717/fr/carboxymaltose-ferrique-teva-carboxymaltose-ferrique-carence-martiale
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, intravenous
infusions, intravenous
Product containing only ferric carboxymaltose in parenteral dose form (medicinal product form)
iron, parenteral preparations
evaluation of the transparency committee
Iron Deficiencies
ferric carboxymaltose

---
https://www.has-sante.fr/jcms/p_3592810/fr/cuvitru-immunoglobuline-humaine-normale-immunoglobuline
2025
false
false
false
France
injections, subcutaneous
treatment outcome
insurance, health, reimbursement
immunoglobulins, normal human, for extravascular adm.
immunologic factors
adult
child
adolescent
immunologic deficiency syndromes
Secondary immune deficiency disorder (disorder)
Primary Immunodeficiency Diseases
evaluation of the transparency committee
immunoglobulins

---
https://www.has-sante.fr/jcms/p_3594402/fr/hyqvia-immunoglobuline-humaine-normale-plasmatique-polyradiculonevrite-inflammatoire-demyelinisante-chronique-pidc
2025
false
false
false
France
infusions, subcutaneous
treatment outcome
insurance, health, reimbursement
immunoglobulins, normal human, for extravascular adm.
adult
adolescent
child
immunologic factors
infant, newborn
infant
evaluation of the transparency committee
polyradiculoneuropathy, chronic inflammatory demyelinating
immunoglobulins

---
https://www.has-sante.fr/jcms/p_3594405/fr/ovitrelle-choriogonadotropine-alfa-induction-d-ovulation-assistance-medicale-a-la-procreation
2025
false
false
false
France
evaluation of the transparency committee
ovulation induction
chorionic gonadotropin
medical assistant
ovulation induction

---
https://www.has-sante.fr/jcms/p_3594399/fr/acupan-nefopam-douleur-aigue-analgesique-central-non-morphinique
2025
false
false
false
France
administration, oral
Product containing precisely nefopam hydrochloride 30 milligram/1 each conventional release oral tablet (clinical drug)
evaluation of the transparency committee
nefopam
analgesics, non-narcotic
acute pain
acupan

---
https://www.has-sante.fr/jcms/p_3594375/fr/tepadina-thiotepa-greffe
2025
false
false
false
France
Product containing only thiotepa in parenteral dose form (medicinal product form)
infusions, intravenous
treatment outcome
insurance, health, reimbursement
transplantation conditioning
transplantation, autologous
transplantation, homologous
intense chemotherapy program
evaluation of the transparency committee
thiotepa
hematopoietic stem cell transplantation

---
https://www.has-sante.fr/jcms/p_3594723/fr/influvac-vaccin-grippal-inactive-a-antigenes-de-surface-vaccin-antigrippal
2025
false
false
false
France
INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B
INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2)
INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1)
Trivalent Influenza Vaccine
evaluation of the transparency committee
influenza vaccines
preventive immunization/medication
hepatitis surface antigen
influenza virus vaccine
vaccines, inactivated
antigens, surface
vaccination

---
https://www.has-sante.fr/jcms/p_3597238/fr/calquence-acalabrutinib-lymphome-a-cellules-du-manteau-lcm
2025
false
false
false
France
evaluation of the transparency committee
Calquence
"u" lymphocyte
lymphoma, mantle-cell
acalabrutinib
acalabrutinib
malignant lymphoma, nos

---
https://www.has-sante.fr/jcms/p_3594961/fr/spevigo-spesolimab-psoriasis-pustuleux-generalise-ppg-chez-l-adulte-et-l-adolescent
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, subcutaneous
spesolimab
Generalized pustular psoriasis
Generalized pustular psoriasis flare
evaluation of the transparency committee
adolescent
spesolimab
adult
psoriasis

---
https://www.has-sante.fr/jcms/p_3594958/fr/vaxigrip-vaccin-grippal-trivalent-inactive-a-virion-fragmente-vaccin-antigrippal
2025
France
evaluation of the transparency committee
vaccination
vaxigrip
preventive immunization/medication
fragmentation, nos
influenza virus vaccine
virion
influenza vaccines
vaccines, inactivated
vaxigrip

---
https://www.has-sante.fr/jcms/p_3597499/fr/hympavzi-marstacimab-hemophilie
2025
false
false
false
France
hemorrhage
evaluation of the transparency committee
marstacimab
hemophilia A

---
https://www.has-sante.fr/jcms/p_3597606/fr/krazati-adagrasib-cancer-bronchique-non-a-petites-cellules-avance-cbnpc
2025
false
false
false
France
bronchial neoplasms
treatment outcome
insurance, health, reimbursement
administration, oral
antineoplastic agents
adagrasib
adult
KRAS G12C Inhibitor
KRAS NP_004976.2:p.G12C
evaluation of the transparency committee
carcinoma, non-small-cell lung
adagrasib

---
https://www.has-sante.fr/jcms/p_3597524/fr/strategie-de-vaccination-contre-les-infections-invasives-a-meningocoques
2025
France
evaluation of the transparency committee
preventive immunization/medication
meningococcal infections
infectious disease, nos
meningococcus vaccination
vaccination
vaccination
health planning guidelines

---
https://www.has-sante.fr/jcms/p_3597444/fr/lidocaine-aguettant-chlorhydrate-de-lidocaine-anesthesie
2025
false
false
false
France
evaluation of the transparency committee
lidocaine hydrochloride
anesthesia
lack of sensation
lidocaine hydrochloride
lidocaine

---
https://www.has-sante.fr/jcms/p_3597161/fr/nicorettespray-/-nicorettespray-fruits-rouges-nicotine-sevrage-tabagique
2025
false
false
false
France
tobacco use disorder
administration, buccal
oral sprays
treatment outcome
insurance, health, reimbursement
adult
nicotine
evaluation of the transparency committee
nicotine
smoking cessation

---
https://www.has-sante.fr/jcms/p_3598458/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2-faible-ou-ultra-faible
2025
false
false
false
France
evaluation of the transparency committee
breast neoplasms
Trastuzumab
trastuzumab deruxtecan
trastuzumab

---
https://www.has-sante.fr/jcms/p_3598534/fr/voxzogo-vosoritide-achondroplasie-chez-les-patients-ages-de-4-mois-a-moins-de-5-ans
2025
false
false
false
France
infant
child
treatment outcome
insurance, health, reimbursement
injections, subcutaneous
vosoritide
evaluation of the transparency committee
vosoritide
achondroplasia

---
https://www.has-sante.fr/jcms/p_3598324/fr/otezla-apremilast-psoriasis-en-plaques-modere-a-severe-chez-les-enfants-et-adolescents-a-partir-de-6-ans
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
apremilast
administration, oral
evaluation of the transparency committee
child
psoriasis
apremilast
adolescent

---
https://www.has-sante.fr/jcms/p_3598809/fr/phelinun-melphalan-cancer-et-greffe
2025
false
false
false
France
Melphalan Hydrochloride
hematopoietic stem cell transplantation
hematologic diseases
infusions, intravenous
insurance, health, reimbursement
treatment outcome
multiple myeloma
hodgkin disease
lymphoma, Non-Hodgkin
precursor cell lymphoblastic Leukemia-Lymphoma
leukemia, myeloid, acute
neuroblastoma
Childhood Neuroblastoma
melphalan
evaluation of the transparency committee
melphalan
transplantation conditioning

---
https://www.has-sante.fr/jcms/p_3598812/fr/nordimet-methotrexate-psoriasis-en-plaque-modere
2025
false
false
false
France
adult
insurance, health, reimbursement
treatment outcome
injections, subcutaneous
methotrexate
evaluation of the transparency committee
psoriasis
methotrexate

---
https://www.has-sante.fr/jcms/p_3599233/fr/champix-tartrate-de-varenicline-sevrage-tabagique
2025
false
false
false
France
evaluation of the transparency committee
weaning
smoking cessation
Varenicline
champix
varenicline tartrate
tobacco use cessation

---
https://www.has-sante.fr/jcms/p_3599701/fr/beclometasone-formoterol-biogaran-beclometasone-/-formoterol-asthme-bronchopneumopathie-chronique-obstructive-bpco
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, inhalation
formoterol and beclometasone
evaluation of the transparency committee
asthma
beclomethasone
pulmonary disease, chronic obstructive
Formoterol Fumarate

---
https://www.has-sante.fr/jcms/p_3599704/fr/ferrostrane-nourrissons-feredetate-de-sodium-carence-martiale
2025
false
false
false
France
insurance, health, reimbursement
treatment outcome
pharmaceutical solutions
administration, oral
sodium feredetate
evaluation of the transparency committee
Iron Deficiencies
ferric sodium edetate
infant
Fe(III)-EDTA

---
https://www.has-sante.fr/jcms/p_3600181/fr/ixchiq-vaccin-contre-le-chikungunya-vivant-attenue-chikungunya
2025
false
false
false
France
vaccination
Chikungunya vaccine (live)
insurance, health, reimbursement
vaccine potency
adult
evaluation of the transparency committee
vaccines, attenuated
Chikungunya Fever
vaccination

---
https://www.has-sante.fr/jcms/p_3600306/fr/fluenz-vaccin-grippal-trivalent-vivant-attenue-nasal-vaccin-antigrippal
2025
France
evaluation of the transparency committee
influenza vaccines
vaccination
vaccines, attenuated
preventive immunization/medication
attenuated by
nose, nos
influenza virus vaccine

---
https://www.has-sante.fr/jcms/p_3601437/fr/beovu-brolucizumab-degenerescence-maculaire-liee-a-l-age-dmla-oedeme-maculaire-diabetique-omd
2025
France
evaluation of the transparency committee
macular degeneration
degeneration, nos
brolucizumab
diabetes mellitus
age, nos
macular degeneration
macule, nos
brolucizumab
macular edema
edema, nos

---
https://www.has-sante.fr/jcms/p_3601434/fr/verzenios-abemaciclib-cancer-du-sein
2025
false
false
false
France
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
menopause
evaluation of the transparency committee
abemaciclib
breast neoplasms
abemaciclib
breast cancer
Verzenio
neoplasm, malignant

---
https://www.has-sante.fr/jcms/p_3601428/fr/kisqali-ribociclib-cancer-du-sein
2025
false
false
false
France
treatment outcome
hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer
evaluation of the transparency committee
neoplasm, malignant
Kisqali
breast cancer
ribociclib
breast neoplasms
ribociclib

---
https://www.has-sante.fr/jcms/p_3601303/fr/edurant-rilpivirine-vih
2025
false
false
false
France
child
adult
evaluation of the transparency committee
human immunodeficiency virus, nos
Rilpivirine
hiv infections

---
https://www.has-sante.fr/jcms/p_3601431/fr/ajovy-fremanezumab-migraine
2025
false
false
false
France
migraine disorders
insurance, health, reimbursement
treatment outcome
fremanezumab
injections, subcutaneous
antibodies, monoclonal
adult
calcitonin gene-related peptide
evaluation of the transparency committee
fremanezumab

---
https://www.has-sante.fr/jcms/p_3601952/fr/seladelpar-gilead-seladelpar-lysine-dihydrate-cholangite-biliaire-primitive
2025
false
false
false
France
Seladelpar Lysine
Seladelpar lysine dihydrate
Primary Biliary Cholangitis
evaluation of the transparency committee
lysine
seladelpar

---
https://www.has-sante.fr/jcms/p_3601988/fr/pedmarqsi-thiosulfate-de-sodium-prevention-de-l-ototoxicite-du-cisplatine
2025
false
false
false
France
Drug-Induced Ototoxicity
Ototoxicity
cisplatin
infant
adolescent
child
evaluation of the transparency committee
thiosulfates
sodium thiosulfate

---
https://www.has-sante.fr/jcms/p_3601719/fr/elahere-mirvetuximab-soravtansine-cancer-de-l-ovaire
2025
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
mirvetuximab soravtansine
mirvetuximab soravtansine
adult
ovarian neoplasms
fallopian tube neoplasms
peritoneal neoplasms
evaluation of the transparency committee
Folate Receptor Alpha Positive

---
https://www.has-sante.fr/jcms/p_3602613/fr/libmeldy-atidarsagene-autotemcel-leucodystrophie-metachromatique-30-mois-6-ans
2025
France
evaluation of the transparency committee
leukodystrophy, metachromatic
metachromatic leukodystrophy, nos

---
https://www.has-sante.fr/jcms/p_3602593/fr/evkeeza-evinacumab-hypercholesterolemie-homozygote-familiale-pediatrie-6-mois-a-4-ans
2025
France
evaluation of the transparency committee
pediatrician
high serum cholesterol, familial
evinacumab
evkeeza
due to
Homozygous Familial Hypercholesterolemia
homozygote
familial hypercholesterolemia
pediatrics
evinacumab

---
https://www.has-sante.fr/jcms/p_3602981/fr/quiloga-rosuvastatine/ezetimibe-hypercholesterolemie
2025
France
evaluation of the transparency committee
hypercholesterolemia
hypercholesterolemia, nos

---
https://www.has-sante.fr/jcms/p_3602978/fr/naprosyne-naproxene-ains
2025
France
evaluation of the transparency committee
naproxen
naproxen
non-steroidal anti-inflammatory agent, nos
anti-inflammatory agents, non-steroidal

---
https://www.has-sante.fr/jcms/p_3453321/fr/pluvicto-177lu-cancer-de-la-prostate
2025
false
false
false
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
metastatic castration resistant prostate cancer
Metastatic Castration-Resistant Prostate Carcinoma
evaluation of the transparency committee
prostatic neoplasms, Castration-Resistant

---
https://www.has-sante.fr/jcms/p_3603177/fr/anzupgo-delgocitinib-eczema-chronique-des-mains-ecm
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, cutaneous
delgocitinib
Chronic hand eczema (disorder)
chronic disease
Janus Kinase Inhibitors
adult
evaluation of the transparency committee
delgocitinib
eczema
hand

---
https://www.has-sante.fr/jcms/p_3603354/fr/fampyra-fampridine-sclerose-en-plaques-sep
2025
false
false
false
France
evaluation of the transparency committee
multiple sclerosis
multiple sclerosis
4-Aminopyridine
fampridine
multiple sclerosis, nos

---
https://www.has-sante.fr/jcms/p_3603360/fr/peditrace-chlorure-de-zinc-chlorure-de-cuivre-dihydrate-selenite-de-sodium-chlorure-de-manganese-tetrahydrate-iodure-de-potassium-nutrition-oligo-elements
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug combinations
infusions, intravenous
Copper chloride dihydrate (substance)
cupric chloride
chlorides
infant, newborn
infant, premature
infant
child
adolescent
parenteral nutrition
electrolytes in combination with other drugs
evaluation of the transparency committee
manganese
potassium iodide
zinc compounds
copper
manganese chloride, tetrahydrate
trace elements
zinc chloride
manganese chloride
sodium selenite

---
https://www.has-sante.fr/jcms/p_3603851/fr/wakix-pitolisant-narcolepsie
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
pitolisant
adult
evaluation of the transparency committee
pitolisant
narcolepsy

---
https://www.has-sante.fr/jcms/p_3605176/fr/exblifep-cefepime/enmetazobactam-lactamines-inhibiteurs-de-lactamase
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
cefepime, enmetazobactam drug combination
drug combinations
Cefepime
enmetazobactam
anti-bacterial agents
beta-Lactamase Inhibitors
adult
Complicated urinary tract infection
pyelonephritis
Healthcare-Associated Pneumonia
pneumonia, ventilator-associated
enterobacteriaceae infections
Infection caused by carbapenemase-producing Enterobacteriaceae (disorder)
OXA-48 carbapenemase-producing bacteria (organism)
infusions, intravenous
cefepime and beta-lactamase inhibitor
bacteremia
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3605182/fr/prevenar-20-vaccin-pneumococcique-polyosidique-conjugue-20-valent-adsorbe-ou-vpc20-infections-a-pneumocoques
2025
false
false
false
France
evaluation of the transparency committee
preventive immunization/medication
vaccination
pneumococcal infections
prevenar
pneumococcal infectious disease, nos
polysaccharides
pneumococcal polysaccharide vaccine
pneumococcal vaccination
pneumococcal vaccines
vaccines, conjugate

---
https://www.has-sante.fr/jcms/p_3604202/fr/rybrevant-amivantamab-cancer-bronchique-non-a-petites-cellules-exon-19-exon-21
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
amivantamab
Non-small cell lung cancer with mutation in epidermal growth factor receptor (disorder)
bronchial neoplasms
infusions, intravenous
Antineoplastic Agents, Immunological
antibodies, bispecific
Amivantamab/Carboplatin/Pemetrexed Regimen
antineoplastic combined chemotherapy protocols
carboplatin
Pemetrexed
adult
EGFR NP_005219.2:p.L858R
EGFR Exon 19 Deletion Mutation
evaluation of the transparency committee
amivantamab
bronchial neoplasms

---
https://www.has-sante.fr/jcms/p_3497032/fr/azelastine-chlorhydrate-/-fluticasone-propionate-eg-chlorhydrate-d-azelastine-/-propionate-de-fluticasone-rhinite-allergique
2024
false
false
false
France
drug combinations
treatment outcome
insurance, health, reimbursement
rhinitis, allergic, seasonal
fluticasone, combinations
administration, intranasal
histamine H1 antagonists, non-sedating
anti-inflammatory agents
evaluation of the transparency committee
azelastine hydrochloride
Fluticasone
rhinitis, allergic, perennial
Fluticasone Propionate
azelastine

---
https://www.has-sante.fr/jcms/p_3497011/fr/jardiance-empagliflozine-maladie-renale-chronique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
empagliflozin
drug therapy, combination
administration, oral
Sodium-Glucose Transporter 2 Inhibitors
chronic kidney diseases
evaluation of the transparency committee
empagliflozin

---
https://www.has-sante.fr/jcms/p_3492882/fr/alvesco-ciclesonide-asthme
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
glucocorticoids
administration, inhalation
ciclesonide
evaluation of the transparency committee
asthma
ciclesonide

---
https://www.has-sante.fr/jcms/p_3497035/fr/iopamiron-iopamidol-produit-de-contraste-iode
2024
false
false
false
France
iopamidol
evaluation of the transparency committee
Iopamidol
iodine, nos
iopamidol
contrast media
iodine

---
https://www.has-sante.fr/jcms/p_3497041/fr/dotarem-acide-gadoterique-produit-de-contraste-pour-imagerie-par-resonnance-magnetique
2024
false
false
false
France
evaluation of the transparency committee
Gadoteric Acid
contrast media
magnetic resonance imaging

---
https://www.has-sante.fr/jcms/p_3497017/fr/omnipaque-iohexol-produit-de-contraste-iode
2024
false
false
false
France
evaluation of the transparency committee
iodine
omnipaque
contrast media
iohexol

---
https://www.has-sante.fr/jcms/p_3497062/fr/iomeron-iomeprol-produit-de-contraste-iode
2024
false
false
false
France
evaluation of the transparency committee
iodine, nos
iomeprol
contrast media
iomeprol
Iomeprol
iomeron
iomeprol
iodine

---
https://www.has-sante.fr/jcms/p_3497026/fr/mircera-methoxy-polyethylene-glycol-epoetine-beta-anemie-symptomatique-associee-a-l-insuffisance-renale-chronique-chez-les-enfants-ages-de-3-mois-a-moins-de-18-ans
2024
false
false
false
France
infant
adolescent
treatment outcome
insurance, health, reimbursement
hematinics
methoxy polyethylene glycol-epoetin beta
Anemia of chronic renal failure (disorder)
evaluation of the transparency committee
continuous erythropoietin receptor activator
polyethylene glycols
anemia
erythropoietin
methoxy polyethylene glycol-epoetin beta
renal insufficiency, chronic
child

---
https://www.has-sante.fr/jcms/p_3497047/fr/xerava-eravacycline-tetracyclines
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
eravacycline
Complicated intra-abdominal infection
complicated intra-abdominal infections
infusions, intravenous
adult
xerava
anti-bacterial agents
Product containing only eravacycline in parenteral dose form (medicinal product form)
evaluation of the transparency committee
tetracyclines
eravacycline

---
https://www.has-sante.fr/jcms/p_3497164/fr/omvoh-mirikizumab-rectocolite-hemorragique
2024
false
false
false
France
mirikizumab
treatment outcome
insurance, health, reimbursement
adult
gastrointestinal agents
infusions, intravenous
injections, subcutaneous
Interleukin Inhibitors
Interleukin-23
evaluation of the transparency committee
colitis, ulcerative
mirikizumab

---
https://www.has-sante.fr/jcms/p_3497065/fr/visipaque-iodixanol-produit-de-contraste-iode
2024
false
false
false
France
iodixanol
-
-
evaluation of the transparency committee
iodine
iodixanol
contrast media

---
https://www.has-sante.fr/jcms/p_3497029/fr/xenetix-iobitridol-produit-de-contraste-iode
2024
false
false
false
France
iobitridol
evaluation of the transparency committee
contrast media
iodine
iobitridol

---
https://www.has-sante.fr/jcms/p_3465275/fr/dupixent-dupilumab-prurigo-nodulaire
2024
false
false
false
France
dupilumab
Prurigo nodularis (disorder)
adult
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
dupilumab
prurigo

---
https://www.has-sante.fr/jcms/p_3452178/fr/clairyg-immunoglobuline-humaine-normale-immunoglobuline-humaine-normale
2024
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
immunoglobulins, normal human, for intravascular adm.
Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form)

---
https://www.has-sante.fr/jcms/p_3443053/fr/enhertu-trastuzumab-deruxtecan-cancer-du-sein-her2
2024
false
false
false
France
adult
treatment outcome
insurance, health, reimbursement
Unresectable HER2-Positive Breast Carcinoma
Metastatic HER2-Positive Breast Carcinoma
neoplasm metastasis
trastuzumab deruxtecan
guidelines for drug use
Antineoplastic Agents, Immunological
infusions, intravenous
evaluation of the transparency committee
breast neoplasms
trastuzumab deruxtecan
Trastuzumab

---
https://www.has-sante.fr/jcms/p_3412521/fr/abecma-idecabtagene-vicleucel-myelome-multiple
https://www.has-sante.fr/jcms/p_3412521/en/abecma-idecabtagene-vicleucel-myelome-multiple
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
idecabtagene vicleucel
infusions, intravenous
Antineoplastic Agents, Immunological
evaluation of the transparency committee
idecabtagene vicleucel
multiple myeloma

---
https://www.has-sante.fr/jcms/p_3418585/fr/yescarta-axicabtagene-ciloleucel-lymphome-ldgcb-lhgcb
2024
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
insurance, health, reimbursement
treatment outcome
Recurrent High Grade B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
Refractory High Grade B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
adult
infusions, intravenous
gene therapy
axicabtagene ciloleucel

---
https://www.has-sante.fr/jcms/p_3423139/fr/spevigo-spesolimab-psoriasis-pustuleux-generalise-ppg
2024
false
false
false
France
Generalized pustular psoriasis
spesolimab
adult
treatment outcome
insurance, health, reimbursement
infusions, intravenous
evaluation of the transparency committee
psoriasis
spesolimab

---
https://www.has-sante.fr/jcms/p_3425618/fr/voraxaze-glucarpidase-intoxication-au-methotrexate
2024
false
false
false
France
package leaflet
summary of product characteristics
protective agents
glucarpidase
Detoxification
methotrexate
Methotrexate toxicity
methotrexate
evaluation of the transparency committee
glucarpidase

---
https://www.has-sante.fr/jcms/p_3390379/fr/ciclograft-ciclosporine-greffe-de-cornee
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
graft rejection
drug therapy, combination
risk factors
guidelines for drug use
ophthalmic solutions
administration, ophthalmic
immunosuppressive agents
evaluation of the transparency committee
corneal transplantation
cyclosporine

---
https://www.has-sante.fr/jcms/p_3577018/fr/lamzede-velmanase-alfa-alpha-mannosidose
2024
false
false
false
France
evaluation of the transparency committee
mannosidosis, nos
temperance
Mannosidosis
alpha-Mannosidosis

---
https://www.has-sante.fr/jcms/p_3471694/fr/orkambi-lumacaftor/ivacaftor-mucoviscidose
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
lumacaftor, ivacaftor drug combination
drug combinations
ivacaftor
lumacaftor
ivacaftor and lumacaftor
infant
administration, oral
evaluation of the transparency committee
cystic fibrosis

---
https://www.has-sante.fr/jcms/p_3506437/fr/rubraca-rucaparib-cancer-de-l-ovaire
2024
false
false
false
France
fallopian tube neoplasms
peritoneal neoplasms
treatment outcome
insurance, health, reimbursement
administration, oral
rucaparib
evaluation of the transparency committee
rucaparib
ovarian neoplasms
Rucaparib Camsylate

---
https://www.has-sante.fr/jcms/p_3506440/fr/repatha-evolocumab-hypercholesterolemie
2024
false
false
false
France
evaluation of the transparency committee
repatha
Hypercholesterolemia
hypercholesterolemia
evolocumab
Evolocumab
evolocumab
hypercholesterolemia, nos

---
https://www.has-sante.fr/jcms/p_3508486/fr/uvedose-cholecalciferol-carence-en-vitamine-d
2024
false
false
false
France
evaluation of the transparency committee
Vitamin D3
vitamin d deficiency, nos
Vitamin D3 Measurement
Vitamin D Deficiency
vitamin d deficiency
Cholecalciferol
vitamin d3
cholecalciferol

---
https://www.has-sante.fr/jcms/p_3508868/fr/acide-tranexamique-tillomed-acide-tranexamique-antifibrinolytique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, intravenous
adult
adolescent
child
hemorrhage
hemorrhage due to fibrinolysis
drugs, generic
tranexamic acid
evaluation of the transparency committee
antifibrinolytic agents
tranexamic acid

---
https://www.has-sante.fr/jcms/p_3508907/fr/folinate-de-calcium-kalceks-folinate-de-calcium-hydrate-oncologie
2024
false
false
false
France
drugs, generic
treatment outcome
insurance, health, reimbursement
calcium folinate
injections, intramuscular
infusions, intravenous
antidotes
methotrexate
Drug-Related side effects and adverse reactions
Methotrexate Toxicity
adult
child
antineoplastic combined chemotherapy protocols
Leukovorin rescue (procedure)
evaluation of the transparency committee
leucovorin
Leucovorin, Calcium (1:1) Salt

---
https://www.has-sante.fr/jcms/p_3508898/fr/bendamustine-accord-bendamustine-hematologie
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
bendamustine
infusions, intravenous
antineoplastic agents, alkylating
Stage C Chronic Lymphocytic Leukemia
Stage B Chronic Lymphocytic Leukemia
lymphoma, Non-Hodgkin
leukemia, lymphocytic, chronic, B-Cell
multiple myeloma
DS Stage II Multiple Myeloma
DS Stage III Multiple Myeloma
evaluation of the transparency committee
Bendamustine Hydrochloride

---
https://www.has-sante.fr/jcms/p_3509116/fr/junaliza-atorvastatine/ezetimibe-hypolipidemiants-en-association
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
Ezetimibe
Atorvastatin
atorvastatin calcium
atorvastatin and ezetimibe
hypercholesterolemia
non-familial primary hypercholesterolemia
Familial hypercholesterolemia - heterozygous (disorder)
Mixed Hyperlipidemia
adult
evaluation of the transparency committee
drug combinations
hypolipidemic agents

---
https://www.has-sante.fr/jcms/p_3511643/fr/acide-acetylsalicylique-biogaran-acide-acetylsalicylique-maladies-cardio-vasculaires-et-cerebrovasculaires
2024
France
evaluation of the transparency committee
cardiovascular system, nos
aspirin
Cerebrovascular Disorder
vascular disease, nos
vascular diseases
acetylsalicylic acid
cerebrovascular disease
Aspirin DL-Lysine
cerebrovascular disease, nos
Aspirin/Folic acid
Cardiovascular
cerebrovascular disorders
Aspirin

---
https://www.has-sante.fr/jcms/p_3512093/fr/talzenna-talazoparib-cancer-de-la-prostate
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
Enzalutamide/Talazoparib Regimen
enzalutamide
metastatic castration resistant prostate cancer
adult
neoplasm metastasis
administration, oral
talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
Product containing only talazoparib in oral dose form (medicinal product form)
evaluation of the transparency committee
talazoparib
prostatic neoplasms, Castration-Resistant

---
https://www.has-sante.fr/jcms/p_3513274/fr/sunitinib-zentiva-sunitinib-oncologie
2024
false
false
false
France
evaluation of the transparency committee
Sunitinib Malate
Oncologist
Sunitinib
Oncology
Sunitinib
Oncologists

---
https://www.has-sante.fr/jcms/p_3516768/fr/vyvgart-efgartigimod-alfa-myasthenie-auto-immune-generalisee
2024
false
false
false
France
evaluation of the transparency committee
Diffuse
myasthenia gravis, generalized
efgartigimod alfa
efgartigimod alfa
Pervasive
myasthenia gravis
Efgartigimod Alfa
Myasthenia Gravis
Vyvgart

---
https://www.has-sante.fr/jcms/p_3516751/fr/akeega-niraparib/acetate-d-abiraterone-cancer-de-la-prostate
2024
false
false
false
France
evaluation of the transparency committee
abiraterone
prostatism, nos
Prostate Carcinoma
prostatic neoplasms
Prostate Cancer pT2c TNM Finding v6 and v7
NCI CTEP SDC Prostate Cancer Sub-Category Terminology
Prostate Cancer Pathway
prostate cancer
neoplasm, malignant
prostate, nos
Abiraterone
abiraterone
malignant neoplasm prostate

---
https://www.has-sante.fr/jcms/p_3515581/fr/finlee-spexotras-dabrafenib-trametinib-gliome-pediatrie
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
antineoplastic combined chemotherapy protocols
dabrafenib
protein kinase inhibitors
antineoplastic agents
child
infant
Childhood Low Grade Glioma
malignant glioma
Childhood Malignant Glioma
BRAF V600E Mutation Present
guidelines for drug use
package leaflet
summary of product characteristics
Trametinib Dimethyl Sulfoxide
administration, oral
trametinib
evaluation of the transparency committee
dabrafenib
Dabrafenib/Trametinib Regimen
glioma
trametinib

---
https://www.has-sante.fr/jcms/p_3516936/fr/agamree-vamorolone-traitement-de-la-dystrophie-musculaire-de-duchenne-dmd
https://ansm.sante.fr/tableau-acces-derogatoire/agamree#
2024
false
false
false
France
evaluation of the transparency committee
Therapy Object
Treat
muscular dystrophy, nos
Duchenne Muscular Dystrophy
muscular dystrophy, duchenne
Treatment Epoch
Biomaterial Treatment
No Treatment for Diabetes
Doctor of Dental Medicine
Treatment
muscular dystrophies
On Treatment
vamorolone
Vamorolone
Laser Capture Microdissection
GDC Treatment Frequency Terminology
Treatment Study
DMD Gene
During Treatment

---
https://www.has-sante.fr/jcms/p_3511387/fr/shingrix-vaccin-zona-recombinant-avec-adjuvant-vaccin-zona
2024
false
false
false
France
vaccination
vaccine potency
insurance, health, reimbursement
herpes zoster
neuralgia, postherpetic
adult
aged
herpesvirus 3, human
zoster, purified antigen
evaluation of the transparency committee
Adjuvants, Vaccine
herpes zoster vaccine
Zoster Vaccine Recombinant, Adjuvanted
vaccines, synthetic
vaccination
vaccines, recombinant

---
https://www.has-sante.fr/jcms/p_3515653/fr/rystiggo-rozanolixizumab-myasthenie
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
orphan drug production
rozanolixizumab
immunosuppressive agents
adult
myasthenia gravis, generalized
generalised myasthenia gravis with anti-acetylcholine receptor antibody
evaluation of the transparency committee
myasthenia gravis
rozanolixizumab

---
https://www.has-sante.fr/jcms/p_3482873/fr/cibinqo-abrocitinib-dermatite-atopique-da
2024
false
false
false
France
abrocitinib
treatment outcome
insurance, health, reimbursement
Janus Kinase Inhibitors
administration, oral
adult
evaluation of the transparency committee
dermatitis, atopic
abrocitinib

---
https://www.has-sante.fr/jcms/p_3486160/fr/jyseleca-filgotinib-rectocolite-hemorragique-rch
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
Janus Kinase Inhibitors
filgotinib
adult
evaluation of the transparency committee
colitis, ulcerative
filgotinib

---
https://www.has-sante.fr/jcms/p_3483264/fr/fluenz-tetra-vaccin-grippal-quadrivalent-vivant-attenue-nasal-vaccin-antigrippal
2024
false
false
false
France
evaluation of the transparency committee
Trivalent Live-Attenuated Influenza Vaccine
preventive immunization/medication
Nasal Route of Administration
Trial Element Duration
Influenza Vaccine
influenza virus vaccine
vaccines, attenuated
Quadrivalent Influenza Vaccine
Nasal Dosage Form
vaccination
nose, nos
influenza vaccines
Tea Leaf
Ezatiostat Hydrochloride
attenuated by

---
https://www.has-sante.fr/jcms/p_3486233/fr/xeljanz-tofacitinib-arthrite-juvenile-idiopathique-aji
2024
false
false
false
France
Product containing only tofacitinib in oral dose form (medicinal product form)
tablets
pharmaceutical solutions
administration, oral
treatment outcome
insurance, health, reimbursement
child
adolescent
Polyarticular juvenile idiopathic arthritis
tofacitinib
evaluation of the transparency committee
arthritis, juvenile
Polyarticular Juvenile Idiopathic Arthritis
tofacitinib

---
https://www.has-sante.fr/jcms/p_3487097/fr/columvi-glofitamab-lymphome-diffus-a-grande-cellule-b-ldgcb
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
infusions, intravenous
Antineoplastic Agents, Immunological
lymphoma, large B-Cell, diffuse
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
glofitamab
evaluation of the transparency committee
glofitamab

---
https://www.has-sante.fr/jcms/p_3486120/fr/tibsovo-ivosidenib-cancer-des-voies-biliaires
2024
false
false
false
France
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
adult
treatment outcome
insurance, health, reimbursement
cholangiocarcinoma
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
administration, oral
antineoplastic agents
ivosidenib
evaluation of the transparency committee
ivosidenib

---
https://www.has-sante.fr/jcms/p_3487172/fr/botox-toxine-botulinique-type-a-blepharospasme-spasme-hemifacial-torticolis-spasmodique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
botulinum toxin
neuromuscular agents
evaluation of the transparency committee
hemifacial spasm
botulinum toxins, type A
blepharospasm
torticollis
Spasmodic Torticollis

---
https://www.has-sante.fr/jcms/p_3478093/fr/blincyto-blinatumomab-lal-en-echec-d-au-moins-2-traitements-avec-itk
2024
false
false
false
France
precursor cell lymphoblastic Leukemia-Lymphoma
leukemia, lymphocytic, acute, L2
B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
antineoplastic agents
blinatumomab
evaluation of the transparency committee
blinatumomab

---
https://www.has-sante.fr/jcms/p_3488172/fr/lynparza-olaparib-cancer-de-l-ovaire
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
olaparib
antineoplastic combined chemotherapy protocols
Bevacizumab/Olaparib Regimen
adult
Carcinoma, Ovarian Epithelial
Stage III Ovarian Cancer AJCC v6 and v7
Stage IV Ovarian Cancer AJCC v6 and v7
fallopian tube neoplasms
peritoneal neoplasms
administration, oral
evaluation of the transparency committee
olaparib

---
https://www.has-sante.fr/jcms/p_3481441/fr/ultibro-breezhaler-indacaterol/bromure-de-glycopyrronium-bronchopneumopathie-chronique-obstructive-bpco
2024
false
false
false
France
indacaterol
insurance, health, reimbursement
treatment outcome
drug combinations
indacaterol-glycopyrronium combination
adult
administration, inhalation
evaluation of the transparency committee
Glycopyrronium
pulmonary disease, chronic obstructive

---
https://www.has-sante.fr/jcms/p_3487178/fr/solu-medrol-methylprednisolone-corticoides
2024
false
false
false
France
injections, intravenous
injections, intramuscular
evaluation of the transparency committee
adrenal cortical hormone, nos
corticoids
methylprednisolone hemisuccinate
medrol
Methylprednisolone
glucocorticoids

---
https://www.has-sante.fr/jcms/p_3478094/fr/pradaxa-dabigatran-etexilate-traitement-des-evenements-thromboemboliques-veineux-etev-pediatrique
2024
false
false
false
France
child
adolescent
evaluation of the transparency committee
pediatrics
During Treatment
Biomaterial Treatment
Treatment
Venous Thromboembolism
Dabigatran Etexilate Mesylate
Treatment Study
pediatrician
On Treatment
venous thromboembolism
GDC Treatment Frequency Terminology
Treatment Epoch
Pediatric
vein, nos
Childhood-Onset Systemic Lupus Erythematosus
Thromboembolic Event, CTCAE
Pradaxa
Pediatric
Pediatricians
Therapy Object
Dabigatran Etexilate
dabigatran etexilate
thromboembolus
No Treatment for Diabetes
Dabigatran
thromboembolism
Treat

---
https://www.has-sante.fr/jcms/p_3478092/fr/taltz-ixekizumab-psoriasis-en-plaques-pediatrique
2024
false
false
false
France
evaluation of the transparency committee
Patch
Pediatric
bone plates
psoriasis
Taltz
Childhood-Onset Systemic Lupus Erythematosus
pediatrics
psoriasis vulgaris
Ixekizumab
ixekizumab
Psoriasis
Pediatricians
ixekizumab
pediatrician
Pediatric

---
https://www.has-sante.fr/jcms/p_3487169/fr/tagrisso-osimertinib-cancer-bronchique-non-a-petites-cellules-cbnpc
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
bronchial neoplasms
administration, oral
antineoplastic agents
osimertinib
adult
evaluation of the transparency committee
carcinoma, non-small-cell lung
osimertinib

---
https://www.has-sante.fr/jcms/p_3478084/fr/zepatier-elbasvir/grazoprevir-hepatite-c-chez-les-adolescents-a-partir-de-12-ans
2024
false
false
false
France
evaluation of the transparency committee
adolescence
Hepatitis C Virus
hepatitis C
viral hepatitis c
Elbasvir/Grazoprevir
adolescent
Zepatier
Autonomic Nervous System
Teenager
Twelve
elbasvir-grazoprevir drug combination
Adolescents
Adolescent
Hepatitis C Infection
Algeria

---
https://www.has-sante.fr/jcms/p_3478096/fr/kalydeco-ivacaftor-mucoviscidose
2024
false
false
false
France
infant
child
evaluation of the transparency committee
ivacaftor
cystic fibrosis
ivacaftor
Ivacaftor
Cystic Fibrosis
cystic fibrosis
kalydeco
ivacaftor

---
https://www.has-sante.fr/jcms/p_3478083/fr/sivextro-phosphate-de-tedizolid-infections-de-la-peau
2024
false
false
false
France
adolescent
evaluation of the transparency committee
tedizolid phosphate
Infection
tedizolid phosphate
infectious disease, nos
Phosphate
Claudin-6
Tiludronate Disodium
phosphates
Tedizolid Phosphate
Skin
Slice
Murine Skin
Ivermectin
Sivextro
skin diseases, infectious
Thaw
Go Skating

---
https://www.has-sante.fr/jcms/p_3488409/fr/libtayo-cemiplimab-cancer-bronchopulmonaire-non-a-petites-cellules-cbnpc
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Antineoplastic Agents, Immunological
cemiplimab
antibodies, monoclonal, humanized
antineoplastic combined chemotherapy protocols
adult
platinum compounds
PD-L1 Positive
evaluation of the transparency committee
carcinoma, non-small-cell lung
cemiplimab

---
https://www.has-sante.fr/jcms/p_3488284/fr/caspofungine-tillomed-caspofungine-antimycotique-a-usage-systemique
2024
false
false
false
France
drugs, generic
infusions, intravenous
caspofungin
evaluation of the transparency committee
Caspofungin
antifungal agents

---
https://www.has-sante.fr/jcms/p_3487904/fr/xolair-omalizumab-polypose-naso-sinusienne
2024
false
false
false
France
nasal polyps
Polyp of nasal cavity and/or nasal sinus (disorder)
evaluation of the transparency committee
xolair
Omalizumab
Polyposis
Omalizumab

---
https://www.has-sante.fr/jcms/p_3488174/fr/nplate-romiplostim-thrombopenie-immunologique-primaire-pti-refractaire-aux-autres-traitements
2024
false
false
false
France
Primary Immune Thrombocytopenia
evaluation of the transparency committee
nplate
principal
Romiplostim
Immunotherapy
romiplostim
Refractory
thrombocytopenia due to immune destruction, nos
Primary Refractory
romiplostim
idiopathic thrombocytopenic purpura, nos
Other Therapy
Immune
Immunology
thrombocytopenia
purpura, thrombocytopenic, idiopathic
immunology

---
https://www.has-sante.fr/jcms/p_3488415/fr/jemperli-dostarlimab-cancer-de-l-endometre
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
dostarlimab
adult
mismatch repair deficient/microsatellite instability-high recurrent or advanced endometrial cancer that has progressed
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
evaluation of the transparency committee
endometrial neoplasms
dostarlimab

---
https://www.has-sante.fr/jcms/p_3488635/fr/cabesol-clobetasol-psoriasis
2024
false
false
false
France
scalp dermatoses
administration, cutaneous
hair preparations
insurance, health, reimbursement
treatment outcome
glucocorticoids
clobetasol
Psoriasis of scalp (disorder)
evaluation of the transparency committee
clobetasol
psoriasis

---
https://www.has-sante.fr/jcms/p_3488641/fr/closalis-calcipotriol/betamethasone-psoriasis
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug combinations
betamethasone dipropionate, calcipotriol drug combination
calcipotriene
betamethasone-17,21-dipropionate
adult
calcipotriol, combinations
administration, cutaneous
ointments
Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and calcipotriol 50 microgram/1 gram conventional release cutaneous ointment (clinical drug)
evaluation of the transparency committee
psoriasis

---
https://www.has-sante.fr/jcms/p_3488638/fr/conydix-ciclopirox-onychomycoses
2024
false
false
false
France
administration, topical
treatment outcome
insurance, health, reimbursement
antifungal agents
Medicated Nail Lacquer Dosage Form
ciclopirox
evaluation of the transparency committee
Ciclopirox
onychomycosis

---
https://www.has-sante.fr/jcms/p_3490351/fr/lytgobi-futibatinib-cholangiocarcinome
2024
false
false
false
France
futibatinib
treatment outcome
insurance, health, reimbursement
adult
Intrahepatic Cholangiocarcinoma
antineoplastic agents
Locally Advanced Intrahepatic Cholangiocarcinoma
Metastatic Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
FGFR2 Gene Rearrangement
FGFR2 Gene Fusion Positive
Cancer Progression
administration, oral
evaluation of the transparency committee
cholangiocarcinoma
futibatinib

---
https://www.has-sante.fr/jcms/p_3490357/fr/budesonide-teva-sante-budesonide-corticoide
2024
false
false
false
France
administration, oral
treatment outcome
insurance, health, reimbursement
Modified-release Hard Capsule Dosage Form
crohn disease
colitis, microscopic
budesonide
evaluation of the transparency committee
glucocorticoids
budesonide
corticoids

---
https://www.has-sante.fr/jcms/p_3490695/fr/casgevy-exagamglogene-autotemcel-thalassemie-dependante-des-transfusions-tdt
2024
false
false
false
France
biological products
insurance, health, reimbursement
treatment outcome
Transfusion Dependent Beta Thalassemia
beta-Thalassemia
exagamglogene autotemcel
adolescent
young adult
infusions, intravenous
adoptive transfer
evaluation of the transparency committee
Exagamglogene Autotemcel

---
https://www.has-sante.fr/jcms/p_3490839/fr/cufence-trientine-dichlorhydrate-maladie-de-wilson
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
chelating agents
trientine
adult
adolescent
child
evaluation of the transparency committee
trientine hydrochloride
hepatolenticular degeneration
trientine

---
https://www.has-sante.fr/jcms/p_3490841/fr/reblozyl-luspatercept-anemie-associee-a-une-beta-thalassemie
2024
false
false
false
France
evaluation of the transparency committee
beta-Thalassemia
luspatercept

---
https://www.has-sante.fr/jcms/p_3490834/fr/trodelvy-sacituzumab-govitecan-cancer-du-sein
2024
false
false
false
France
adult
treatment outcome
insurance, health, reimbursement
infusions, intravenous
sacituzumab govitecan
HER2/Neu Negative
Hormone Receptor Positive
evaluation of the transparency committee
breast neoplasms
sacituzumab govitecan

---
https://www.has-sante.fr/jcms/p_3490820/fr/opdualag-nivolumab/relatlimab-melanome
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug combinations
relatlimab
nivolumab and relatlimab
Nivolumab
Antineoplastic Agents, Immunological
infusions, intravenous
Unresectable Cutaneous Melanoma
adult
adolescent
PD-L1 Expression Less than 1 Percent
Advanced Cutaneous Melanoma
evaluation of the transparency committee
melanoma

---
https://www.has-sante.fr/jcms/p_3490827/fr/yselty-linzagolix-choline-fibromes-uterins
2024
false
false
false
France
administration, oral
adult
linzagolix
receptors, LHRH
evaluation of the transparency committee
Linzagolix Choline
fibroid uterus
linzagolix
leiomyoma

---
https://www.has-sante.fr/jcms/p_3490824/fr/crysvita-burosumab-hypophosphatemie-liee-a-l-x
2024
false
false
false
France
child
adolescent
treatment outcome
insurance, health, reimbursement
rickets, X-Linked hypophosphatemic
burosumab
injections, subcutaneous
antibodies, monoclonal, humanized
evaluation of the transparency committee
burosumab
familial hypophosphatemic rickets
X-Linked Dominant Hypophosphatemic Rickets

---
https://www.has-sante.fr/jcms/p_3490836/fr/enoxaparine-crusia-enoxaparine-sodique-thrombose-veineuse-profonde-tvp-et-embolie-pulmonaire-ep
2024
false
false
false
France
evaluation of the transparency committee
enoxaparin
embolism and thrombosis
pulmonary embolism
Deep Vein Thrombosis
venous thrombosis
pulmonary embolism
Enoxaparin Sodium
Venous Embolism
Pulmonary Embolism
deep vein thrombosis
deep thrombophlebitis, nos
pulmonary embolism

---
https://www.has-sante.fr/jcms/p_3478085/fr/liporosa-rosuvastatine/ezetimibe-maladie-coronaire-avec-antecedent-de-syndrome-coronarien-aigu-sca
2024
false
false
false
France
evaluation of the transparency committee
Coronary
high pitch
Superior Cerebellar Artery
Disease Object
Acute Coronary Syndrome
disease
coronary disease
Disease Steps Clinical Classification
disease, nos
No Evidence of Coronary Artery Disease
case histories
Disease Free
acute coronary syndrome

---
https://www.has-sante.fr/jcms/p_3490837/fr/esbriet-pirfenidone-fibrose-pulmonaire-idiopathique-fpi-severe
2024
false
false
false
France
evaluation of the transparency committee
Borg Category-Ratio 10 Perceived Exertion Score 5
Epidermal cGVHD Score 4
fibrosis of lung, nos
Severe Adverse Event
Pirfenidone
idiopathic pulmonary fibrosis
severe
esbriet
Severe Dysplasia
pirfenidone
unknown (origin)
Severe Hallucination
Idiopathic Pulmonary Fibrosis
Severe Extremity Pain
Intensity and Distress 5
pirfenidone

---
https://www.has-sante.fr/jcms/p_3491589/fr/vivotif-salmonella-enterica-serovar-typhi-souche-ty21a-vaccin-anti-typhoidique-vivant-attenue
2024
false
false
false
France
Ty21a typhoid vaccine
polysaccharides, bacterial
treatment outcome
insurance, health, reimbursement
vaccination
administration, oral
typhoid, oral, live attenuated
typhoid fever
immunization, active
evaluation of the transparency committee
vaccination
salmonella typhi
typhoid-paratyphoid vaccines

---
https://www.has-sante.fr/jcms/p_3492656/fr/scyova-foslevodopa/foscarbidopa-maladie-de-parkinson
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug combinations
Foscarbidopa
Foslevodopa
antiparkinson agents
pharmaceutical solutions
foslevodopa and decarboxylase inhibitor
infusions, subcutaneous
evaluation of the transparency committee
parkinson disease

---
https://www.has-sante.fr/jcms/p_3492662/fr/ciclopirox-substipharm-ciclopirox-antifongique-a-usage-topique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, cutaneous
Medicated Nail Lacquer Dosage Form
ciclopirox
onychomycosis
evaluation of the transparency committee
Ciclopirox
antifungal agents

---
https://www.has-sante.fr/jcms/p_3492683/fr/kynmobi-chlorhydrate-d-apomorphine-maladie-de-parkinson
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, sublingual
apomorphine
adult
dopamine agonists
Sublingual Film Dosage Form
evaluation of the transparency committee
apomorphine
parkinson disease
apomorphine hydrochloride

---
https://www.has-sante.fr/jcms/p_3491848/fr/giapreza-acetate-d-angiotensine-ii-hypotension-refractaire-dans-les-chocs-distributifs
2024
false
false
false
France
Giapreza
angiotensin II
insurance, health, reimbursement
treatment outcome
vasoconstrictor agents
shock
infusions, intravenous
shock, septic
Distributive shock
adult
Product containing only angiotensin II in parenteral dose form (medicinal product form)
evaluation of the transparency committee
Angiotensin II Acetate
angiotensin II
hypotension

---
https://www.has-sante.fr/jcms/p_3494990/fr/orserdu-elacestrant-cancer-du-sein
2024
false
false
false
France
elacestrant
insurance, health, reimbursement
treatment outcome
postmenopause
Activating ESR1 Gene Mutation
Locally Advanced Estrogen Receptor-Positive Breast Carcinoma
Metastatic Estrogen Receptor-Positive Breast Carcinoma
HER2/Neu Negative
administration, oral
selective estrogen receptor modulators
evaluation of the transparency committee
elacestrant
breast neoplasms

---
https://www.has-sante.fr/jcms/p_3495284/fr/tak-755-apadamtase-alfa-purpura-thrombotique-thrombocytopenique-congenital-pttc
2024
false
false
false
France
enzyme replacement therapy
congenital thrombotic thrombocytopenic purpura
adolescent
adult
enzymes
evaluation of the transparency committee
purpura, thrombotic thrombocytopenic
Apadamtase Alfa

---